VVigilance Weekly공개 리포트 보기
← 이번 주 리포트
tirzepatide우선순위 중간ICSR 검토기타

LITERATURE DETAIL · PMID 42618523

Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes.

Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes.

저자
Mainak Banerjee, Ajitesh Roy, Vivek Mohan Sharma, Abhishek Das
저널
Obesity (Silver Spring, Md.)
공개일
2026 Aug 19
연구 유형
기타
DOI
10.1002/oby.70277

문헌 요약

This study aimed to compare the effectiveness of tirzepatide versus injectable semaglutide in preventing major adverse liver outcomes (MALO) among adults with overweight or obesity and type 2 diabetes. This retrospective target trial emulation utilized the TriNetX global network to analyze new users of tirzepatide and semaglutide. The primary outcome was…

PV 검토 포인트

개별 증례 가능성과 중대성, 예상성 및 중복 여부를 우선 검토합니다.

PubMed에서 원문 정보 보기